New York-Presbyterian Hospital

After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.

The test, EXaCT-1, may not only help doctors find treatments for patients who have run out of options but may also provide biomarkers of immunotherapy response.

The Irving Institute, a CUMC partnership with New York-Presbyterian, will fund its precision medicine program and the development of new therapies.

NEW YORK (GenomeWeb News) – Weill Cornell Medical College and New York-Presbyterian Hospital have partnered to launch a new institute that will pursue genome-centered translational medicine to deliver personalized care.

In the May issue of Cancer Prevention Research, Steven Lipkin and colleagues reported that in colon cancer cell lines, the protective effect against colorectal cancer was stronger in cells with a particular SNP in the HMGCR gene.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.